Managing the side effects in patients being treated for metastatic breast cancer can be challenging. Recently, Marla D. Lipsyc-Sharf, MD, a breast medical oncologist and health sciences clinical ...
A protein once thought to simply help cancer cells avoid death turns out to do much more. MCL1 actively drives cancer ...
Kazia Therapeutics Ltd. raised AU$50 million (US$33.15 million) in a private placement of equity securities to advance lead candidate paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor in clinical ...
Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 trials. Gedatolisib shows promising efficacy and safety, especially in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback